Get the Stockscreener App
1.68
4.54%
-0.0662
Calcimedica Inc stock is traded at $1.68, with a volume of 3,664.
It is down -4.54% in the last 24 hours and up +6.18% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
See More
Previous Close:
$1.7462
Open:
$1.7084
24h Volume:
3,664
Relative Volume:
0.10
Market Cap:
$23.25M
Revenue:
-
Net Income/Loss:
$-13.59M
P/E Ratio:
-1.5556
EPS:
-1.08
Net Cash Flow:
$-19.79M
1W Performance:
-7.39%
1M Performance:
+6.18%
6M Performance:
-51.68%
1Y Performance:
-70.60%
1-Day Range:
$1.65
$1.7084
1-Week Range:
$1.65
$1.83
52-Week Range:
$1.43
$5.97
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
1.6644 | 23.89M | 0 | -13.59M | -19.79M | -1.08 |
|
ONC
Beone Medicines Ltd Adr
|
246.87 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.41 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.91 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
492.90 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Calcimedica Inc Stock (CALC) Latest News
HC Wainwright Reiterates “Buy” Rating for CalciMedica (NASDAQ:CALC) - Defense World
CalciMedica (CALC) Receives Reiteration of Buy Rating with $16 P - GuruFocus
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates - Citizen Tribune
CalciMedica (CALC) Expected to Announce Quarterly Earnings on Monday - Defense World
CalciMedica Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Purchases New Stake in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
Geode Capital Management LLC Boosts Stock Holdings in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
Bristol-Myers Squibb (NYSE:BMY) vs. CalciMedica (NASDAQ:CALC) Critical Review - Defense World
CalciMedica (NASDAQ:CALC) Shares Up 0.7% – Here’s Why - Defense World
CalciMedica's Breakthrough Research Takes Center Stage at Two Elite Medical Conferences - Stock Titan
CalciMedica Announces Presentations at Upcoming Medical Meetings - PR Newswire
Analysts Offer Predictions for CalciMedica Q4 Earnings - Defense World
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Corient Private Wealth LLC Buys New Shares in CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (NASDAQ:CALC) Receives “Buy” Rating from HC Wainwright - Defense World
Corient Private Wealth LLC Acquires Shares of 38,000 CalciMedica, Inc. (NASDAQ:CALC) - The AM Reporter
Graybug Vision stock hits 52-week low at $1.81 - Investing.com India
Graybug Vision stock hits 52-week low at $1.81 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $16 target on CalciMedica stock - Investing.com Australia
CalciMedica’s Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating - TipRanks
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference - PR Newswire
CalciMedica says cash sufficient to fund operating plan into mid-2026 - TipRanks
CALCIMEDICA Earnings Results: $CALC Reports Quarterly Earnings - Nasdaq
CalciMedica Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates - Citizen Tribune
Calcimedica Reports 2024 Financial Results And Provides Clinical & Corporate Updates - MarketScreener
CalciMedica (CALC) to Release Earnings on Thursday - The AM Reporter
CalciMedica Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Atria Investments Inc Buys 7,509 Shares of CalciMedica, Inc. (NASDAQ:CALC) - Defense World
CalciMedica (CALC) Expected to Announce Quarterly Earnings on Thursday - Defense World
Graybug Vision stock hits 52-week low at $1.83 amid challenges - Investing.com
Rani Therapeutics (NASDAQ:RANI) versus CalciMedica (NASDAQ:CALC) Financial Contrast - Defense World
Promising Phase 2 Results and Market Potential Drive Buy Rating for CalciMedica’s Auxora - TipRanks
Short Interest in CalciMedica, Inc. (NASDAQ:CALC) Increases By 35.0% - Defense World
Latham & Watkins Advises CalciMedica in Secured Growth Financing - Latham & Watkins LLP
CalciMedica secures $32.5 million credit facility By Investing.com - Investing.com Canada
CalciMedica secures credit facility for up to $32.5M - MSN
CalciMedica Secures Credit Facility For Up To $32.5 Million -March 05, 2025 at 07:44 am EST - Marketscreener.com
CalciMedica secures $32.5 million credit facility - Investing.com India
CalciMedica Secures Credit Facility for Up to $32.5 Million - Finansavisen
CalciMedica (NASDAQ:CALC) Given “Buy” Rating at HC Wainwright - Defense World
Graybug Vision stock hits 52-week low at $1.95 amid challenges - Investing.com
CalciMedica reports reduced mortality in AKI trial with Auxora - Investing.com
CalciMedica Highlights Auxora’s Potential in COVID-19 Treatment - TipRanks
CalciMedica reports reduced mortality in AKI trial with Auxora By Investing.com - Investing.com South Africa
CalciMedica’s Auxora shows mortality reduction in COVID-19 pneumonia trial - TipRanks
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica, Inc. (CALC): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference - PR Newswire
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Longview News-Journal
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Calcimedica Inc Stock (CALC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sanderling Venture Partners VI | 10% Owner |
Nov 01 '24 |
Buy |
3.75 |
86,867 |
325,751 |
814,300 |
| Sanderling Venture Partners VI | 10% Owner |
Nov 01 '24 |
Buy |
3.75 |
877 |
3,289 |
22,479 |
| MIDDLETON FRED A | Director |
Nov 01 '24 |
Buy |
3.75 |
87,744 |
329,040 |
814,300 |
| MIDDLETON FRED A | Director |
Nov 01 '24 |
Buy |
3.75 |
20,000 |
75,000 |
31,714 |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER |
Nov 01 '24 |
Buy |
3.75 |
20,000 |
75,000 |
130,926 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Nov 01 '24 |
Buy |
3.75 |
53,333 |
199,999 |
164,706 |
| WILSON ROBERT N | Director |
Nov 01 '24 |
Buy |
3.75 |
53,333 |
199,999 |
417,529 |
| Dunn Michael J. | President and COO |
Sep 09 '24 |
Option Exercise |
1.39 |
11,761 |
16,348 |
11,761 |
| Leheny A. Rachel | CHIEF EXECUTIVE OFFICER |
Aug 27 '24 |
Buy |
4.19 |
1,000 |
4,190 |
110,926 |
| Roberts Eric W | CHIEF BUSINESS OFFICER |
Aug 23 '24 |
Buy |
3.57 |
5,000 |
17,867 |
46,894 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):